Combination of interferon α with mannan peptide in treatment of HBeAg-positive chronic hepatitis B

( views:, downloads: )
Author:
LING Xiao(Health Bureau of Guilin City,Guilin 341002,China)
TANG Zhen-xiang()
CHENG Shu-quan()
XIAN Yong-chao()
YE Xin()
CAI Yi-feng()
HUANG Cheng-jun()
NI Hui()
Journal Title:
CHINESE JOURNAL OF CLINICAL INFECTIOUS DISEASES
Issue:
Volume 2, Issue 05, 2009
DOI:
10.3760/cma.j.issn.1674-3397.2009.05.004
Key Word:
Chronic hepatitis B; Hepatitis B e antigen; Combined therapy; Mannan peptide; Interferon α

Abstract: Objective To investigate the clinical effect of IFNα combined with mannan peptide in treatment of patients with HBeAg-positive chronic hepatitis B ( CHB ). Methods Eighty HBeAg-positive CHB patients with HBV DNA quantity ranging from 10 to 10 eopies/mL were enrolled and randomized into the treatment group and the control group ( n = 40 for each ). Patients in treatment group were given daily subcutaneous injection of IFNα-2b 5,000,000 U for 52 weeks, and received mannan peptide 10 mg per intravenous injection or 2. 5 mg per intramuscular injection for a total of 2 to 3 treatment courses (12 weeks for each). The control group received only IFNα-2b treatment. Liver function, serum markers of hepatitis B, HBV DNA quantity and blood tests were performed before the treatment and at 2, 4, 8, 16, 26 and 52-week during the treatment; and the adverse effects were recorded. Results The rates for ALT normalization, negative HBsAg, negative HBeAg, HBeAg seroconversion and negative HBV DNA were 91. 8% , 17. 5% , 52. 5% , 27. 5 % and 47. 5% at 52nd week in the treatment group, while those in the control group were 80. 0% , 12. 5% , 30. 0% , 10. 0 % and 25. 0% , respectively. There were significant differences in HBeAg-negative, HBeAg-seroeonversion and HBV DNA-negative rates between two groups (χ2 = 4. 178, 4.021 and 4.381, P < 0. 05 ) , and these indexes in the treatment group were increased to 57. 5% , 30. 0% and 50. 0 respectively at 52nd week after drug withdraw. White blood cells began to be elevated at 4th week and were restored to the normal levels at 8th week in the treatment group, while the count in the control was lower than the normal value even at 52nd week of the treatment with the average of (3.45±1. 18)×109/L. Conclusion Alpha-interferon combined with mannan peptide therapy is effective for patients with HBeAg-positive CHB, which may restore the declined peripheral WBC counts induced by interferon and improve the compliance.

  • [1]Lau GKK.HBeAg-positive chronic hepatitis B:why do I treat my patients with pegylated interferon.Liver int,2009,29(Suppl 1):125-129.
  • [2]Hur WH,Woo HY,Jeong SW,et al.A cage report of treatment with pegylated interferon alpha for lamivudine-resistant chronic hepatitis B virus infection.Korean J Hepatol,2008,14(4):513-518.
  • [3]Chinese Society of Infectious Diseases and Parasitology and Chinese Society of Hepatology of Chinese Medical Association.The programme of prevention and cure for viral hepatitis.Chuanranbing Xinxi,2000,13(4):141-150.(in Chinese)中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案.传染病信息,2000,13(4):141-150.
  • [4]Okushin H,Ohnishi T,Morii K,et al.Short-term intravenous interferon therapy for chronic hepatitis B.World J Gastroenterol.2008,14(19):3038-3043.
  • [5]Degertekin B,Lok AS.Do guidelines preclude hepatitis B patients from receiving treatment?Hepatology,2009,49(2):700-701.
  • [6]Cui JJ,Jiang XL,Zhou BP,et al.Thymosin-d 1 improving efficacy of peginterferon alfa-2a treatment in patients with HBeAgpositive chronic hepatitis B.Zhongguo Yiyuan Yaoxue Zazhi,2008,28(10):823-826.(in Chinese)崔建军,蒋小玲,周伯平,等.聚乙二醇十扰素α-2a联合胸腺肽α1治疗HBeAg阳性慢性乙型肝炎.中国医院药学杂志,2008,28(10):823-826.
  • [7]Huang QF.Leukocytopenia and thrombocytopenia from recombinant interferon α-1b.Yaowu Buliang Fanying Zazhi.2006,8(6):455.(in Chinese)黄全福.重组人干扰素α-1b引起白细胞及血小板减少.药物不良反应杂志,2006,8(6):455.
  • [8]Wong DK,Cheung AM,O'Rourke K,et al.Effect of alphainterferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B.A meta-analysis.Ann Intern Med,1993,119(4):312-323.
  • [9]Cheng SQ.The status and evaluation of interferon used in viral hepatitis.Xin Yixue,2005,36(12):715-717,730.(in Chinese)程书权.十扰索在病毒性肝炎中的应用现状与评价.新医学,2005,36(12):715-717,730.
  • [10]van Zonneveld M,Honkoop P,Hansen BE,et al.Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.Hepatology,2004,39(3):804-810.
  • [11]Xu TIM,Wet Z,Huan HC,et al.Clinical analysis of polyethyleneglycol interferon α-2a treated in chronic hepatitis B.Linchuang Huicui,2009,24(4):287-289.(in Chinese)徐天敏,卫峥,黄和冲,等.聚乙二醇干扰素α-2a治疗慢性乙型肝炎临床分析.临床荟萃,2009,24(4):287-289.
  • [12]Wu DS,Li MS,Zhang JY.The efficacy of interferon for treating chronic hepatitis B.Zhongguo Xiandai Yaowu Yingyong,2008,2(15):42-44.(in Chinese)吴东牛,李明寿,张俊英.干扰素治疗慢性乙型病毒性肝炎疗效观察.中国现代药物应用,2008,2(15):42-44.
  • [13]Cooksley WG,Piratvisuth T,Lee SD,et al.Peginterferon alpha2a(40 kDa):an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.J Viral Hepat,2003,10(4):298-305.
  • [14]Zhao H,Si CW,Wei L,et al,A muhicenter,randomized,openlabel study of the safety and effectiveness of pegylated interferon alpha 2b and interferon alpha 2b in treating HBeAg positive chronic hepatitis B patients.Zhonghua Ganzangbing Zazhi,2006,12(5):323-326.(in Chinese)赵鸿,斯崇文,魏来,等.聚乙二醇化下扰素α-2b与干扰素α-2b治疗e抗原阳件慢性乙型肝炎的疗效和安全性的随机对照多中心研究.中华肝脏病杂志,2006,12(5);323-326.
  • [15]Yang GY,Niu Z.Patients with liver cirrhosis immune function impairment and effect of used multiple anti-met endothelin.Zhonghna Ganzangbing Zazhi,1995,3(4)235-236.(in Chinese)杨刚毅,钮振.肝硬化患者免疫机能减损及应用多抗甲素后的影响.中华肝脏病杂志,1995,3(4)235-236.
  • [16]Wang YS,Wang XY.The pharmacological action and clinical use of mannan peptide.Zhongguo Yaoshi,2004,7(4):302-305.(in Chinese)王允生,王晓燕.甘露聚糖肽(多抗甲素)的药理作用与临床应用.中国药师,2004,7(4):302-305.
  • [17]Ainge GD,Parlane NA,Denis M,et al.Phosphatidylinositol mannoside ether analogues:syntheses and interleukin-12-inducing properties.J Org Chem,2007,72(14):5291-5296.
  • [18]Boonyarattanakalin S,Liu X,Michieletti M,et al.Chemical synthesis of all phosphatidylinositol mannoside(PIM)glyeans from mycobacterium tuberculosis.J Am Chem Soc,2008,130(49):16791-16799.
  • [19]Miyoshi E,Ihara Y,Hayashi N,et al.Transfection of Nacetylglucosaminyhransferase Ⅲ gone suppresses expression of hepatitis B virus in a human hepatoma cell line,HB611.J Biol Chem,1995,270(47):28311-28315.
  • [20]Shim JK,Lee YC,Chung TH,et al.Elevated expression of bisecting N-acetylglucosaminyhransferase-Ⅲ gene in a human fetal hcpatocyte cell line by hepatitis B virus.J Gastroenterol Hepatol,2004,19(12):1374-1387.
  • [21]Parlane NA,Denis M,Severn WB,et al.Phosphatidylinositol mannosides are efficient mucosal adjuvants.Immunol Invest,2008,37(2):129-142.
  • [22]Liu R,Wang SL,Liu F,et al.Observation of curative effect in mannan peptide promoted hepatitis B vaccine inoculator antibody formation.Binzhou Yixueyuan Xuebao,2006,29(3):230-231.(in Chinese)刘锐,王善玲,刘峰,等.甘露聚糖肽对促进乙肝疫苗接种者抗体形成的疗效观察.滨州医学院学报,2006,29(3):230-231.
  • [23]Wang QL,Li YJ.Analysis adverse reaction of mannan peptide.Zhongguo Xiandai Yaowu Yingyong,2008,2(5):15-18.(in Chinese)王乾蕾,李运景.甘露聚糖肽致不良反应分析.中国现代药物应用,2008,2(5):15-18.
  • [24]Han ZG.Mannose-induced adverse reaction analysis of 26 cases of literature.Zhongguo Minkang Yixue,2008,20(20):2460.(in Chinese)韩在刚.甘露聚糖肽致不良反应26例文献分析.中国民康医学,2008,20(20):2460.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn